Logo image of CHA

CHAGEE HOLDINGS LTD-ADR (CHA) Stock Fundamental Analysis

NASDAQ:CHA - Nasdaq - US15743P1049 - ADR - Currency: USD

27.55  -0.87 (-3.06%)

After market: 27.68 +0.13 (+0.47%)

Fundamental Rating

4

Taking everything into account, CHA scores 4 out of 10 in our fundamental rating. CHA was compared to 0 industry peers in the Unkown industry. While CHA has a great health rating, there are worries on its profitability. CHA has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CHA had positive earnings in the past year.
CHA had a positive operating cash flow in the past year.
CHA Yearly Net Income VS EBIT VS OCF VS FCFCHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1B 2B

1.2 Ratios

Industry RankSector Rank
ROA 36.15%
ROE 66.45%
ROIC 54.54%
ROA(3y)7.97%
ROA(5y)N/A
ROE(3y)-66.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHA Yearly ROA, ROE, ROICCHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -100 -200 -300

1.3 Margins

Industry RankSector Rank
OM 23.27%
PM (TTM) 19.22%
GM 49.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CHA Yearly Profit, Operating, Gross MarginsCHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 20 -20 40

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CHA is creating value.
CHA has about the same amout of shares outstanding than it did 1 year ago.
CHA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CHA Yearly Shares OutstandingCHA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 50M 100M 150M
CHA Yearly Total Debt VS Total AssetsCHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2B 4B 6B

2.2 Solvency

CHA has an Altman-Z score of 11.80. This indicates that CHA is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for CHA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.8
ROIC/WACC6.27
WACC8.7%
CHA Yearly LT Debt VS Equity VS FCFCHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 1B 2B 3B

2.3 Liquidity

CHA has a Current Ratio of 2.37. This indicates that CHA is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.31 indicates that CHA has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.37
Quick Ratio 2.31
CHA Yearly Current Assets VS Current LiabilitesCHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 228.63% over the past year.
The Revenue has grown by 167.35% in the past year. This is a very strong growth!
EPS 1Y (TTM)228.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)167.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CHA will show a very strong growth in Earnings Per Share. The EPS will grow by 133.36% on average per year.
CHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 140.79% yearly.
EPS Next Y783.99%
EPS Next 2Y226.73%
EPS Next 3Y133.36%
EPS Next 5YN/A
Revenue Next Year793.89%
Revenue Next 2Y234.44%
Revenue Next 3Y140.79%
Revenue Next 5YN/A

3.3 Evolution

CHA Yearly Revenue VS EstimatesCHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
CHA Yearly EPS VS EstimatesCHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 5 10 15 20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

CHA is valuated correctly with a Price/Earnings ratio of 14.89.
CHA is valuated rather cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 10.33 indicates a reasonable valuation of CHA.
CHA's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 14.89
Fwd PE 10.33
CHA Price Earnings VS Forward Price EarningsCHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF 14.13
EV/EBITDA 10.76
CHA Per share dataCHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

CHA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CHA's earnings are expected to grow with 133.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y226.73%
EPS Next 3Y133.36%

More info and screens

0

5. Dividend

5.1 Amount

CHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHAGEE HOLDINGS LTD-ADR

NASDAQ:CHA (7/11/2025, 8:00:00 PM)

After market: 27.68 +0.13 (+0.47%)

27.55

-0.87 (-3.06%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.21%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.12B
Analysts82.5
Price Target41.62 (51.07%)
Short Float %0.54%
Short Ratio0.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 14.89
Fwd PE 10.33
P/S 2.96
P/FCF 14.13
P/OCF 12.93
P/B 10.22
P/tB 10.28
EV/EBITDA 10.76
EPS(TTM)1.85
EY6.72%
EPS(NY)2.67
Fwd EY9.68%
FCF(TTM)1.95
FCFY7.08%
OCF(TTM)2.13
OCFY7.74%
SpS9.32
BVpS2.69
TBVpS2.68
PEG (NY)0.02
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 36.15%
ROE 66.45%
ROCE 67.16%
ROIC 54.54%
ROICexc N/A
ROICexgc N/A
OM 23.27%
PM (TTM) 19.22%
GM 49.57%
FCFM 20.93%
ROA(3y)7.97%
ROA(5y)N/A
ROE(3y)-66.72%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover1.88
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 396.13%
Cap/Sales 1.94%
Interest Coverage 250
Cash Conversion 96.27%
Profit Quality 108.9%
Current Ratio 2.37
Quick Ratio 2.31
Altman-Z 11.8
F-Score9
WACC8.7%
ROIC/WACC6.27
Cap/Depr(3y)307.37%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)228.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y783.99%
EPS Next 2Y226.73%
EPS Next 3Y133.36%
EPS Next 5YN/A
Revenue 1Y (TTM)167.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year793.89%
Revenue Next 2Y234.44%
Revenue Next 3Y140.79%
Revenue Next 5YN/A
EBIT growth 1Y168.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.75%
OCF growth 3YN/A
OCF growth 5YN/A